Skip Navigation
Print This Page
Share this page: More

Identifying Therapies for Autism

We recently completed a pilot trial focused on the assessment of Minocycline, an antibiotic that has immunomodulatory properties by regulating microglial activation, as a potential medication to reduce the progression of neurobehavioral and neurological deterioration in a small group of patients (n=10) with regressive forms of autism.

Although the results of the trial showed no significant clinical effects, changes in the pre- and post-treatment profiles of the proform of neurotrophic growth factor BDNF in CSF and blood as well as other growth factors such as HGF and IL8, suggest that minocycline may have effects in the central nervous system by modulating the production of neurotropic growth factors. Larger studies are needed to determine if minocycline treatment could be helpful for children with autism, and particularly for those with baseline evidence of neuroinflammation.


Related Links

Attacking Two Brain Disorders on Multiple Fronts
Uncover how Hopkins researchers are finding new treatments and diagnostic tools to treat multiple sclerosis and transverse myelitis.

Looking Forward

Read the latest issue of our newsletter

Looking Forward Fall 2014 cover

Previous Issues

Out-of-State and International Patients - Find Out More


© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.